Trv Gp V LLC Purchases Shares of 7,135,233 Rapport Therapeutics (NASDAQ:RAPP)

TRV GP V LLC purchased a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,135,233 shares of the company's stock, valued at approximately $126,579,000. Rapport Therapeutics accounts for about 43.1% of TRV GP V LLC's holdings, making the stock its 2nd largest holding. TRV GP V LLC owned 19.51% of Rapport Therapeutics as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. TRV GP VI LLC purchased a new position in Rapport Therapeutics during the fourth quarter valued at approximately $17,194,000. Geode Capital Management LLC bought a new stake in Rapport Therapeutics during the third quarter valued at about $4,133,000. Jennison Associates LLC bought a new position in Rapport Therapeutics in the fourth quarter worth about $1,105,000. State Street Corp bought a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at about $1,189,000. Finally, Norges Bank purchased a new position in shares of Rapport Therapeutics in the 4th quarter worth approximately $860,000.

Insider Transactions at Rapport Therapeutics

In related news, Director Wendy B. Young bought 6,000 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was bought at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Troy A. Ignelzi purchased 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here.

Analysts Set New Price Targets

RAPP has been the subject of several recent analyst reports. JMP Securities initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "market outperform" rating and a $28.00 target price for the company. Citizens Jmp started coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "mkt outperform" rating for the company. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $32.67.

Rapport Therapeutics Stock Performance

Rapport Therapeutics stock traded down $0.17 during trading on Wednesday, reaching $11.38. The company had a trading volume of 176,162 shares, compared to its average volume of 178,169. The firm has a market capitalization of $415.32 million and a PE ratio of -0.82. The firm's 50-day simple moving average is $10.30 and its 200 day simple moving average is $16.63. Rapport Therapeutics has a 1-year low of $6.43 and a 1-year high of $29.74.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.